Study Evaluating AGG-523 in Subjects With Osteoarthritis
Phase 1
Completed
- Conditions
- Osteoarthritis
- Registration Number
- NCT00427687
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
This study will evaluate the effect of AGG-523 administration on biomarkers related to osteoarthritis. Safety and tolerability of AGG-523 will also be assessed.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method The effect of AGG-523 on biomarkers related to osteoarthritis.
- Secondary Outcome Measures
Name Time Method